Empowering Pharma and Biotech partners from target to trial faster, smarter and with greater confidence

At Aphex Pharma Solution, we leverage cutting-edge in silico technologies to transform traditional drug discovery. Our computational biology services are designed to:

• Reduce R&D costs
• Accelerate discovery timelines
• Improve clinicalsuccess probability

We identify the most promising therapeutic candidates early in the pipeline, saving time and resources while guiding better decision-making.

Bringing a new drug to market today can cost over $1 billion and take more than a decade. Despite this enormous investment, many approved therapies benefit only a limited subset of the population. These challenges along with declining R&D productivity and the rise of imprecision medicine highlight an urgent need for smarter, faster, and more cost-effective approaches to drug development

The Game Changer

Testing millions of molecules in the wet lab is impractical and expensive. Our computational pipeline helps you:

• Prioritize only the best candidates
• Avoid wasted effort on non-viable compounds
• Reach experimental validation faster on cell lines, animal models, and eventually human trials

How Do We Work

We combine biology, chemistry, AI, and high-performance computing to:

• Screen millions of compounds
• Perform structural optimization
• Predict drug-target interactions
• Optimize lead candidates for efficacy, selectivity, and safety

We use systems biology and omics data integration to uncover and validate novel disease targets across a wide range of conditions, including:

• Cancer
• Neurodegenerative disorders
• Autoimmune diseases
• Chronic inflammation
• Infectious diseases
• Metabolic disorders
• Cardiovascular diseases
• Rare genetic disorders

From target identification to lead optimization, our platform accelerates discovery and delivers innovative, non-toxic, patentable small molecules

Your Shortcut to Smart Targeting

• Targeted disease-specific compound libraries
• Non-toxic ADMET-filtered hits
• Target-specific novel compounds suitable for validation
• Support for difficult targets like protein–protein interactions
• Unique chemical structures with strong binding potential and low redundancy

Please contact us at drugdiscovery@aphexpharma.com